Clinical trial NCT01929135: Short-term Effect of 2% Atorvastatin Dentifrice in Periodontal Status.
Official title: Short-term Effect of 2% Atorvastatin Dentifrice as an Adjunct to Periodontal Therapy: A Randomized Double-blind Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Chronic Periodontitis
Keywords: Periodontal Disease
Chronic Periodontitis
Atorvastatin
Statins
Hydroxymethylglutaryl-coenzyme A Reductase Inhibitors
Dentifrice
Lead sponsor: Universidad de los Andes, Chile
Sponsor class: OTHER
Collaborators: name: Corporación de Fomento de la Producción, Chile
First posted: 2013-08-27
Enrollment: 38
Sex: ALL
Minimum age (years): 35
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Periodontal disease (PD) is an inflammatory, infectious and destructive condition of the tissues surrounding the teeth. However, even if bacteria are required to initiate periodontal disease, the immune response is responsible for most of the destruction of the periodontal tissues. Statins may be used to control the immune response to periodontal pathogens, a factor that has not yet been managed clinically and even less massively.

Recently it has been reported the pharmacological effectiveness of topically used statins. For periodontal disease, at least four well conducted clinical trials have been published using a topically statin formula for pocket irrigation in adult populations with chronic periodontal disease, observing surprising clinical results in all of them (with clinical and statistical significance) and no adverse reactions.

The purpose of the present study is asses the effectiveness of a medicated 2% atorvastatin dentifrice, as complement to non-surgical conventional periodontal treatment. Clinical examination will be made at the beginning and after one month of treatment.

Detailed description: An medicated 2% atorvastatin dentifrice (2 mg x every 0.1 ml of dentifrice) will be prepared for dental brushing. It will be used as a base a fluoride dentifrice, to which will be added atorvastatin in the prescribed amount. Medicated prototypes and placebos will be dosed in 5 ml syringes indicating each 0.5 ml measures to facilitate dispensing the product and ensure proper use. Thus, each syringe will be for 10 doses of toothpaste (10 brushings). 6 syringes will be provided to each patient, so that they have enough for a month of treatment, during which they will have to brush 2 times a day.

Sample size:

A clinical trial with two parallel groups (1:1) will be conducted, where there will be 2 groups of 19 patients each. The estimated sample size was based on the difference in attachment level achieved in the study Goodson et al (Goodson, Haffajee, Socransky, Kent, Teles, Hasturk, Bogren, Van Dyke, Wennstrom, Lindhe. Control of periodontal infections: A randomized controlled trial I. The primary outcome attachment gain and pocket depth reduction at Treated sites. J Clin Periodontol 2012, 39: 526-536), with a power of 90%, a significance level of 0.05 two-tailed.

Treatments and protocols:

Patients will be treated at the Department of Periodontology of Health Care Center, Universidad de Los Andes in San Bernardo, Santiago, Chile.

The two groups will undergo non-surgical periodontal therapy consisting of scaling and root planning of all tooth groups.

Therapy will be supplemented with oral hygiene instruction, indicating patients to brush with the dentifrice that will be provided, 2 times a day for two minutes each time. Then they will be told to spit the dentifrice excesses during 30 seconds, but not to rinse their teeth, or consume liquids or solid foods for at least 30 minutes. A group of 19 patients will receive the medicated 2%atorvastatin dentifrice while the other group of 19 patients will receive dentifrice without the drug to act as a placebo.

The record of the application of statins will be done by a professor at the Faculty of Dentistry, before periodontal clinical evaluation, in order not to influence the researcher.

The allocation to each group will be random and there will be a sequence concealment.

Analysis Plan:

Continuous variables will be described by measures of central tendency and dispersion. Dichotomous variables will be tabulated and described by absolute frequencies and percentages according to each group. The delta of the outcome variables will be calculated as the difference between measurements before and after intervention. Multiple linear regression models will be used to compare the deltas of outcome variables after adjusting for gender, diabetes and tobacco use. A p value of \<0.05 is considered statistically significant. The analysis will be performed with Stata software (version 12; Stata Corporation, Lakeway Drive, College Station, Texas, USA).

Eligibility criteria: Inclusion Criteria:

* Patients included in the study will be those fully agreeing to participate by signing an informed consent, which has been submitted to and approved, together with the study protocol by the Ethics Committee of the Faculty of Dentistry of Universidad de Los Andes.
* The target population consists of 38 adult patients who consult the Service of Periodontology at the Universidad de Los Andes.
* The eligible population are those that meet the following criteria:

  1. more than 35 years of age.
  2. with at least 14 natural teeth in mouth (excluding third molars).
  3. have some degree of periodontal disease.

Exclusion Criteria:

* Will be excluded those who:

  1. Relate migration plans.
  2. Presence of limiting disease for the understanding and execution of the study or are hospitalized.
  3. Received periodontal treatment in the last year.
  4. Completed antibiotic therapy or Non Steroidal Anti-inflammatory Drugs (NSAIDs) in the last two weeks.
  5. Are using calcium channel blockers, phenytoin, cyclosporine or any associated drug that may affect gingival tissue.
  6. Have autoimmune pathology.
  7. Require antibiotic prophylaxis for periodontal treatment.
  8. Patients requiring treatment with NSAIDs for postoperative pain control after the procedure done.
  9. Patients on statin therapy for dyslipidemia.
  10. Pregnant patients.

Primary outcomes:
measure: Change in Periodontal Inflammation Surface Area (PISA)
timeFrame: baseline and 1 month later of intervention
Secondary outcomes:
measure: Change in Mean Pocket Depth (PD)
timeFrame: baseline and 1 month later
measure: Change in Clinical Attachment Level (CAL)
timeFrame: baseline and 1 month after intervention
measure: Change in Bleeding on Probing Index (BOP)
timeFrame: baseline and 1 month after intervention
measure: Change in Gingival Index
timeFrame: baseline and 1 month after intervention
Other outcomes:
Locations:
city: Santiago
country: Chile
facility: Centro de Salud Universidad de los Andes, San Bernardo
state: Región Metropolitana
city: Santiago
country: Chile
facility: CIBRO Universidad de los Andes
state: Región Metropolitana
Study officials:
affiliation: Universidad de Los Andes
name: David R Rosenberg, DDS, MDS
role: PRINCIPAL_INVESTIGATOR
References: